These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 230791)

  • 1. In vitro and in vivo myocardial effects of a cyclic AMP phosphodiesterase inhibitor structurally related to natural cardenolides.
    Prigent AF; Nemoz G; Roche M; Pacheco H
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):131-52. PubMed ID: 230791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polypeptide (AP-A) from sea anemone (Anthopleura xanthogrammica) with potent positive inotropic action.
    Shibata S; Norton TR; Izumi T; Matsuo T; Katsuki S
    J Pharmacol Exp Ther; 1976 Nov; 199(2):298-309. PubMed ID: 10426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
    Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
    J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of milrinone on ethanol and halothane induced cardiodepression.
    Neira S; Penna M
    Acta Physiol Pharmacol Latinoam; 1988; 38(2):193-211. PubMed ID: 2847492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
    Katano Y; Endoh M
    J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: comparison with MDL 17,043.
    Endoh M; Yanagisawa T; Morita T; Taira N
    J Pharmacol Exp Ther; 1985 Jul; 234(1):267-73. PubMed ID: 2989507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
    Weishaar RE; Quade MM; Schenden JA; Evans DB
    J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency modulation of the inotropic action of isoproterenol in mouse heart.
    Barovsky K; Gross SR
    J Pharmacol Exp Ther; 1981 May; 217(2):314-25. PubMed ID: 6262482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.
    Endoh M; Yamashita S; Taira N
    J Pharmacol Exp Ther; 1982 Jun; 221(3):775-83. PubMed ID: 6283063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
    Mushlin P; Boerth RC; Wells JN
    Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. 1st communication: studies on isolated guinea pig cardiac muscles.
    Ogawa T; Ohhara H; Tsunoda H; Kuroki J; Shoji T
    Arzneimittelforschung; 1989 Jan; 39(1):33-7. PubMed ID: 2566308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of inotropic action of xestoquinone, a novel cardiotonic agent isolated from a sea sponge.
    Kobayashi M; Nakamura H; Kobayashi J; Ohizumi Y
    J Pharmacol Exp Ther; 1991 Apr; 257(1):82-9. PubMed ID: 1850480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
    Follath F; Kersting F; Lewis GR; Dollery CT
    Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
    [No Abstract]   [Full Text] [Related]  

  • 16. Myocardial effects of flavonoids from Crataegus species.
    Schüssler M; Hölzl J; Fricke U
    Arzneimittelforschung; 1995 Aug; 45(8):842-5. PubMed ID: 7575743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
    Nagata K; Ogawa T; Omosu M; Fujimoto K; Hayashi S
    Arzneimittelforschung; 1985; 35(7):1034-6. PubMed ID: 2996562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation of cyclic AMP and contractile responses to isoprenaline: effects of a dihydropyridine derivative, nicardipine (YC-93), on canine ventricular muscle.
    Endoh M; Yanagisawa T; Taira N
    Eur J Pharmacol; 1980 Oct; 67(2-3):225-33. PubMed ID: 6257529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.
    Armah BI; Muster D; Raap A; Brückner R; Graziadei I
    Arzneimittelforschung; 1989 Nov; 39(11):1384-92. PubMed ID: 2559738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.